Cryoglobulinaemia – European Clinical Trials Information Network

Study of Obinutuzumab treatment for patients with non-infectious cryoglobulinemia vasculitis who did not respond to or cannot tolerate Rituximab

Wed, 27 May 2026 04:04:48 +0000

This study focuses on patients with non-infectious cryoglobulinemia vasculitis, a condition where abnormal proteins in the blood cause inflammation of blood vessels. The study will test a medication called Obinutuzumab (Gazyvaro) in patients whose condition has not improved with or who cannot tolerate another medication called Rituximab. The medication will be given through an intravenous infusion directly into a vein.

The purpose of this research is to determine if Obinutuzumab is effective and safe for treating this type of vasculitis. During the study, patients will receive Obinutuzumab as a concentrated solution that will be diluted for infusion. The maximum single dose will be 1,000 mg, with a total maximum dose of 2,000 mg over a treatment period of up to 7 days.

The study will monitor patients for 48 weeks to check how well the treatment works and if there are any side effects. Doctors will look for improvements in various body systems that can be affected by the disease, including the skin, joints, kidneys, nerves, digestive system, lungs, and heart. They will also track changes in specific blood tests that show disease activity.

Study of Isatuximab for Patients with Type I Cryoglobulinemia

Wed, 29 Apr 2026 15:02:16 +0000

This clinical trial is focused on studying a condition called Type I Cryoglobulinemia. This is a rare blood disorder where abnormal proteins in the blood can cause various symptoms, including issues with the skin, joints, kidneys, and other organs. The study is testing a treatment using a medication called Isatuximab, which is given as a solution through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how well Isatuximab works in treating the symptoms of Type I Cryoglobulinemia. Participants in the study will receive the medication over a period of time, and their health will be monitored to see if there is a complete clinical response, meaning that the symptoms of the disease improve significantly. The study will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. The study will track various health indicators, such as the presence of disease symptoms, kidney function, and overall quality of life. The study aims to provide valuable information on the effectiveness and safety of Isatuximab for people with Type I Cryoglobulinemia.

Study of Belimumab versus Placebo for Treatment of Non-infectious Active Cryoglobulinemia Vasculitis in Adult Patients

Wed, 29 Apr 2026 14:57:31 +0000

This study focuses on cryoglobulinemia vasculitis, which is a condition where abnormal proteins in the blood cause inflammation of blood vessels. The study will evaluate a medication called belimumab, given as an injection under the skin, compared to a placebo. The purpose is to determine if belimumab is effective in treating people with non-infectious active cryoglobulinemia vasculitis.

The treatment involves receiving rituximab therapy first, followed by either belimumab injections or placebo. Belimumab is given as a 200 mg injection under the skin. The total duration of treatment is 24 weeks. During the study, doctors will monitor how well the treatment works in controlling the symptoms of blood vessel inflammation.

Participants will have regular check-ups to monitor their health and any changes in their condition. The study will look at how well the treatment works in clearing the abnormal proteins from the blood and improving inflammation. Doctors will also track any side effects that may occur during the treatment period.